ERNESTO MARTÍNEZ BUITRAGO

Dr. ERNESTO MARTÍNEZ BUITRAGO

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2019 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
SVSandra Valderrama-Beltrán
Sandra Valderrama-Beltrán
SGSandra Gualtero
Sandra Gualtero
CACarlos Alvarez-Moreno
Carlos Alvarez-Moreno
FGFabian Gil
Fabian Gil
ARAlvaro J. Ruiz
Alvaro J. Ruiz
CACesar A. Arias
Cesar A. Arias
Methicillin-resistant Staphylococcus aureus (MRSA) skin and soft tissue infections (SSTIs) represent a major clinical problem in Colombia. The aim of this study was to evaluate the risk factors associated with MRSA SSTI in Colombia. A multicenter cohort study with nested case-control design was performed. Patients with an SSTI with at least 48h of inpatient care were included. Patients with an MRSA SSTI were considered the case group and patients with either a non-MRSA SSTI or with an Methicillin-susceptible S. aureus (MSSA) SSTI were the control groups. A multivariate logistic regression approach was used to evaluate risk factors associated with MRSA SSTI with two different statistical models. A total 1134 patients were included. Cultures were positive for 498 patients, of which 52% (n=259) were Staphylococcus aureus. MRSA was confirmed in 68.3% of the S. aureus cultures. In the first model, independent risk factors for MRSA SSTI were identified as the presence of abscess (P<0.0001), cellulitis (P=0.0007), age 18-44 years (P=0.001), and previous outpatient treatment in the previous index visit (P=0.003); surgical site infection was a protective factor (P=0.008). In the second model, the main risk factor found was previous outpatient treatment in the previous index visit (P=0.013). Community-acquired SSTIs in Colombia are commonly caused by MRSA. Therefore, clinicians should consider MRSA when designing the initial empirical treatment for purulent SSTI in Colombia, although there seems to be low awareness of this fact.

16 March 2022 in Implementation Science Communications
Verified
Journal Article
Open access
PDF file
JMJorge Luis Martinez-Cajas
Jorge Luis Martinez-Cajas
JTJulian Torres
Julian Torres
HMHector Fabio Mueses
Hector Fabio Mueses
PCPilar Camargo-Plazas
Pilar Camargo-Plazas
MAMarcela Arrivillaga
Marcela Arrivillaga
BLBeatriz Eugenia Alvarado Llano
Beatriz Eugenia Alvarado Llano
Background: Few studies have used implementation science frameworks to identify determinants of PrEP prescription by healthcare providers. In this work, we developed and psychometrically examined a questionnaire using the theoretical domains framework (TDF) and the consolidated framework for implementation research (CFIR). We used this questionnaire to investigate what factors influence the intention of healthcare providers to offer PrEP care and advocate for PrEP. Methods: We conducted a cross-sectional study in 16 HIV healthcare organizations in Colombia. A 98-item questionnaire was administered online to 129 healthcare professionals. One hundred had complete data for this analysis. We used exploratory factor analysis to assess the psychometric properties of both frameworks, and multinomial regression analysis to evaluate the associations of the frameworks’ domains with two outcomes: (1) intention to offer PrEP care and (2) intention to advocate for PrEP impmentation. Results: We found support for nine indices with good internal consistency, reflecting PrEP characteristics, attitudes towards population needs, concerns about the use of PrEP, concerns about the role of the healthcare systems, knowledge, beliefs about capabilities, professional role, social influence, and beliefs about consequences. Notably, only 57% of the participants were likely to have a plan to care for people in PrEP and 66.7% were likely to advocate for PrEP. The perception of the need for PrEP in populations, the value of PrEP as a practice, the influence of colleagues, and seeing PrEP care as a priority was related to being less likely to be unwilling to provide or advocate for PrEP care. Conclusion: Our findings suggested the importance of multilevel strategies to increase the provision of PrEP care by healthcare providers including adquisition of new skills, training of PrEP champions, and strength the capacity of the health system.

30 November 2012 in European Respiratory Journal
Verified
Journal Article
Open access
PDF file
SVSonia L. Villegas
Sonia L. Villegas
BFBeatriz Ferro
Beatriz Ferro
CPCarlos M. Perez-Velez
Carlos M. Perez-Velez
CMCesar A. Moreira
Cesar A. Moreira
LFLiliana Forero
Liliana Forero
JCJose Antonio Caminero
Jose Antonio Caminero
International audienceFrom the total of 73 MDR-TB isolates, DNA could be extracted from 68 (93.1%). Among 10 genotypes identified, a specific Beijing family genotype SIT190 represented a cluster of 22 cases (20 from Buenaventura). Eight of 20 Beijing strains were involved in a cluster of new cases, suggesting recent ongoing transmission

9 September 2019 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
EBERNESTO MARTÍNEZ BUITRAGO
ERNESTO MARTÍNEZ BUITRAGO
JGJose Millan Onate Gutierrez
Jose Millan Onate Gutierrez
JGJosé Fernando García-Goez
José Fernando García-Goez
JÁJorge Álvarez
Jorge Álvarez
WLWilliam Lenis
William Lenis
LRLuisa Consuelo Rubiano
Luisa Consuelo Rubiano
Background: The HLA-B*57:01 allele is associated with a hypersensitivity reaction to abacavir. Due to the lack of knowledge of HLA-B*57:01 prevalence in Colombia, routine screening is not performed and is not recommended by the national guidelines. We aimed to determine the prevalence of HLA-B*57:01 in HIV population from Colombia.Methods: This cross-sectional study included naïve HIV-infected adults from 13 cities of the country. The presence of HLA-B*57:01 was determined by using SSP-PCR in blood samples. Prevalence rates were stratified by sex, race, and region of origin.Results: HLA-B*57:01 allele prevalence in Colombian HIV-infected individuals was 2.7%. When stratifying for the race, the prevalence was 4% for whites, 2.6% for other race (mainly mestizo), and 1.9% for Afro-Colombians. The prevalence varied from 0% up to 11.4% depending on the department of origin. The highest prevalence rates were found in Caldas (11.4%), Antioquia (5%), Risaralda (4.8%), and Valle del Cauca (4.3%). When distributed by country zones, the central, with a racial predominance of Caucasians and mestizos, was the highest (6.0%, 0R = 4.1, CI 1.2–12.8,p = 0,016).Conclusions: The overall prevalence of HLA-B*57:01 in Colombia was lower than the reported rates for other Latin American countries such as Brazil, Costa Rica, and Argentina, but similar in comparison to Chile and Mexico. The diversity in the racial and ethnic heritage shown in our data supports the recommendation to implement routine screening for the HLA-B*57:01 allele before initiation of abacavir-containing antiretroviral therapy in the Colombian HIV management guidelines.

22 January 2022 in AIDS Care
Verified
Journal Article
Open access
JMJorge Martínez-Cajas
Jorge Martínez-Cajas
BABeatriz Alvarado-Llano
Beatriz Alvarado-Llano
EBERNESTO MARTÍNEZ BUITRAGO
ERNESTO MARTÍNEZ BUITRAGO
JTJulian Torres-Isasiga
Julian Torres-Isasiga
MAMarcela Arrivillaga
Marcela Arrivillaga
HMHéctor Mueses-Marín
Héctor Mueses-Marín
In 2019, Colombia approved the combination of tenofovir disoproxil fumarate/emtricitabine for HIV Pre-Exposure Prophylaxis (PrEP). Therefore, we conducted a situational analysis in HIV-care providers to identify barriers and facilitators for PrEP implementation. A survey was applied to a non-probabilistic sample of health care workers of HIV-specialized clinics. We examined PrEP awareness and familiarity, comfort with PrEP-related activities, perceived barriers for PrEP implementation, concerns, and attitudes. Poisson regressions assessed the relationship between these factors and the variable “having a plan to offer PrEP”. The participation rate was 41% and included physicians (42.6%) and other health professionals (57.4%). Fifty-one percent of the participants reported more than five years of experience caring for people living with HIV. Forty-two percent of non-physician health care workers were nurses. Most reported high familiarity/comfort with PrEP-relevant activities. Concerns about PrEP were prevalent (> 50%) and included causing more harm than good, reducing condom use, medication non-adherence, drug resistance, and healthcare system barriers. Physicians had a plan to offer PrEP (72.2%) more often than other health professionals (52.6). Having a plan to offer PrEP was related to PrEP knowledge and comfort assessing sexual behavior and providing HIV counseling. Overall, about half of HIV-care providers seemed ready to offer PrEP and constitute an asset for PrEP implementation efforts in Colombia. PrEP awareness among non-physicians, PrEP concerns, and negative attitudes need to be addressed to enhance implementation.

7 May 2020 in Colombia Medica
Verified
Journal Article
Open access
PDF file
JAJuan Carlos Alzate Angel
Juan Carlos Alzate Angel
EBERNESTO MARTÍNEZ BUITRAGO
ERNESTO MARTÍNEZ BUITRAGO
MPMaría Paulina Posada-Vergara
María Paulina Posada-Vergara
Throughout the COVID-19 pandemic, the main risk factors associated with the progression to severe disease or death have been typically advanced age, diabetes mellitus, obesity, high blood pressure, heart disease, and chronic pneumopathy. Because of their immunosuppression status, persons with HIV were also expected to have a higher susceptibility to infection or a poor clinical evolution. So far, this has not been confirmed to happen, giving way to hypotheses about the role of immunosuppression or the use of antiretrovirals, which could explain this paradox. In this article we present the existing data on the epidemiology and characteristics of HIV-COVID-19 co-infection, discuss the available evidence on the possible factors involved in the evolution of individuals affected by both viruses, analyze other determinants that may negatively affect persons with HIV during the pandemic, and present recommendations for the prevention and care of COVID-19 infection in the context of HIV.